Exagen Inc. (XGN)
NASDAQ: XGN · Real-Time Price · USD
5.15
+0.44 (9.34%)
Dec 20, 2024, 4:00 PM EST - Market closed
Exagen Revenue
Exagen had revenue of $12.51M in the quarter ending September 30, 2024, a decrease of -6.78%. This brings the company's revenue in the last twelve months to $55.75M, up 8.00% year-over-year. In the year 2023, Exagen had annual revenue of $52.55M with 15.33% growth.
Revenue (ttm)
$55.75M
Revenue Growth
+8.00%
P/S Ratio
1.67
Revenue / Employee
$311,458
Employees
179
Market Cap
90.83M
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 52.55M | 6.99M | 15.33% |
Dec 31, 2022 | 45.56M | -2.74M | -5.66% |
Dec 31, 2021 | 48.30M | 6.32M | 15.07% |
Dec 31, 2020 | 41.98M | 1.59M | 3.93% |
Dec 31, 2019 | 40.39M | 7.95M | 24.50% |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Dec 31, 2014 | Pro | Pro | Pro |
Dec 31, 2013 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
CytomX Therapeutics | 126.62M |
Theratechnologies | 84.32M |
EDAP TMS | 70.72M |
Coya Therapeutics | 9.55M |
Cibus | 4.15M |
Monogram Technologies | 365.00K |
XGN News
- 9 days ago - Exagen Inc. Achieves Key Milestone with 1,000,000th Patient Tested by AVISE® CTD - GlobeNewsWire
- 5 weeks ago - Exagen Inc. Completes Validation and Regulatory Submission for New Lupus and Rheumatoid Arthritis Biomarkers on the AVISE® CTD Platform - GlobeNewsWire
- 5 weeks ago - Exagen, Inc. (XGN) Q3 2024 Earnings Call Transcript - Seeking Alpha
- 2 months ago - Exagen Announces Acceptance of Five Abstracts at 2024 American College of Rheumatology Convergence - GlobeNewsWire
- 3 months ago - Exagen Inc. to Participate in the 2024 Cantor Global Healthcare Conference - GlobeNewsWire
- 4 months ago - Exagen, Inc. (XGN) Q2 2024 Earnings Call Transcript - Seeking Alpha
- 5 months ago - Exagen Inc. to Participate in the Canaccord Genuity 44th Annual Growth Conference - GlobeNewsWire
- 5 months ago - Exagen Appoints Jeffrey G. Black as New Chief Financial Officer - GlobeNewsWire